JP2015520196A - デングウイルスに対するワクチン投与のための組成物および方法 - Google Patents

デングウイルスに対するワクチン投与のための組成物および方法 Download PDF

Info

Publication number
JP2015520196A
JP2015520196A JP2015516276A JP2015516276A JP2015520196A JP 2015520196 A JP2015520196 A JP 2015520196A JP 2015516276 A JP2015516276 A JP 2015516276A JP 2015516276 A JP2015516276 A JP 2015516276A JP 2015520196 A JP2015520196 A JP 2015520196A
Authority
JP
Japan
Prior art keywords
dengue
vaccine
dengue virus
virus
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2015516276A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015520196A5 (enExample
Inventor
ティ． スティンチコム、ダン
ティ． スティンチコム、ダン
イー． オソリオ、ジョージ
イー． オソリオ、ジョージ
ディ． パーチドス、カラランボス
ディ． パーチドス、カラランボス
エヌ． ブレウー、ジョセフ
エヌ． ブレウー、ジョセフ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takeda Vaccines Inc
Original Assignee
Takeda Vaccines Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US13/492,884 external-priority patent/US8968996B2/en
Application filed by Takeda Vaccines Inc filed Critical Takeda Vaccines Inc
Publication of JP2015520196A publication Critical patent/JP2015520196A/ja
Publication of JP2015520196A5 publication Critical patent/JP2015520196A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24141—Use of virus, viral particle or viral elements as a vector
    • C12N2770/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
JP2015516276A 2012-06-10 2013-06-10 デングウイルスに対するワクチン投与のための組成物および方法 Pending JP2015520196A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US13/492,884 2012-06-10
US13/492,884 US8968996B2 (en) 2009-06-01 2012-06-10 Compositions and methods for rapid immunization against dengue virus
PCT/US2013/045041 WO2013188315A1 (en) 2012-06-10 2013-06-10 Compositions and methods for administration of vaccines against dengue virus

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2018030539A Division JP2018090618A (ja) 2012-06-10 2018-02-23 デングウイルスに対する免疫原性組成物およびワクチンキット

Publications (2)

Publication Number Publication Date
JP2015520196A true JP2015520196A (ja) 2015-07-16
JP2015520196A5 JP2015520196A5 (enExample) 2016-07-28

Family

ID=48652375

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2015516276A Pending JP2015520196A (ja) 2012-06-10 2013-06-10 デングウイルスに対するワクチン投与のための組成物および方法
JP2018030539A Withdrawn JP2018090618A (ja) 2012-06-10 2018-02-23 デングウイルスに対する免疫原性組成物およびワクチンキット

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2018030539A Withdrawn JP2018090618A (ja) 2012-06-10 2018-02-23 デングウイルスに対する免疫原性組成物およびワクチンキット

Country Status (6)

Country Link
EP (1) EP2858668A1 (enExample)
JP (2) JP2015520196A (enExample)
CA (1) CA2915027A1 (enExample)
NZ (1) NZ630831A (enExample)
TW (1) TW201402143A (enExample)
WO (1) WO2013188315A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019511533A (ja) * 2016-04-13 2019-04-25 タケダ ワクチン, インコーポレイテッドTakeda Vaccines, Inc. 小児及び若年成人のデングウイルスに対するワクチンの組成物及び方法

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014093182A1 (en) * 2012-12-14 2014-06-19 Inviragen, Inc. Compositions, methods of administration and uses for trivalent dengue virus formulations
KR102389908B1 (ko) 2013-03-15 2022-04-26 다케다 백신즈 인코포레이티드 백신 내의 뎅기 바이러스 키메라 구조체를 위한 조성물 및 방법
EP3316897A4 (en) 2015-07-02 2019-03-13 Primevax Immuno-Oncology, Inc. COMPOSITIONS AND METHODS FOR COMBINATION THERAPY WITH DENGUE VIRUS AND DENDRITIC CELLS
JP2018535191A (ja) 2015-09-26 2018-11-29 プライムヴァックス イミュノ−オンコロジー，インク． 樹状細胞を産生するための組成物及び方法
TWI625393B (zh) * 2016-11-15 2018-06-01 國立清華大學 對抗複數種登革熱病毒血清型之疫苗套組及其製備方法與用途
JP2020500847A (ja) 2016-11-16 2020-01-16 プライムヴァックス イミュノ−オンコロジー，インク． 癌の処置のための併用免疫療法
CA3049225A1 (en) 2017-01-04 2018-07-12 PrimeVax Immuno-Oncology, Inc. Compositions and methods for therapy with dengue virus
US11464815B2 (en) 2018-09-05 2022-10-11 Takeda Vaccines, Inc. Dengue vaccine unit dose and administration thereof
US11426461B2 (en) 2018-09-05 2022-08-30 Takeda Vaccines, Inc. Methods for preventing dengue and hepatitis A
ES2908304T3 (es) 2018-09-05 2022-04-28 Takeda Vaccines Inc Dosis unitaria de vacuna contra el dengue y administración de la misma

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010505801A (ja) * 2006-10-04 2010-02-25 サノフィ・パスツール ４種のデング血清型に対する免疫付与の方法
WO2010141386A1 (en) * 2009-06-01 2010-12-09 Inviragen, Inc. Compositions and methods for administration of vaccines against dengue virus
US20120093864A1 (en) * 2005-04-29 2012-04-19 Polytopos Llc Methods and Compositions for Polytopic Vaccination

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8968996B2 (en) * 2009-06-01 2015-03-03 Takeda Vaccines, Inc. Compositions and methods for rapid immunization against dengue virus

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120093864A1 (en) * 2005-04-29 2012-04-19 Polytopos Llc Methods and Compositions for Polytopic Vaccination
JP2010505801A (ja) * 2006-10-04 2010-02-25 サノフィ・パスツール ４種のデング血清型に対する免疫付与の方法
WO2010141386A1 (en) * 2009-06-01 2010-12-09 Inviragen, Inc. Compositions and methods for administration of vaccines against dengue virus

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
GUY BRUNO: "EVALUATION OF INTERFERENCES BETWEEN DENGUE VACCINE SEROTYPES IN A MONKEY MODEL", AMERICAN JOURNAL OF TROPICAL MEDICINE & HYGIENE, vol. V80 N2, JPN5015010214, 1 February 2009 (2009-02-01), US, pages 302 - 311, ISSN: 0003530991 *
VACCINE, vol. 29, JPN6017011345, 2011, pages 7251 - 7260, ISSN: 0003530990 *
ZHOU HAO: "SCULPTING THE IMMUNOLOGICAL RESPONSE TO DENGUE FEVER BY POLYTOPIC VACCINATION", VACCINE, vol. V24 N14, JPN5015010215, 24 March 2006 (2006-03-24), GB, pages 2451 - 2459, ISSN: 0003530992 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019511533A (ja) * 2016-04-13 2019-04-25 タケダ ワクチン, インコーポレイテッドTakeda Vaccines, Inc. 小児及び若年成人のデングウイルスに対するワクチンの組成物及び方法
JP2022089964A (ja) * 2016-04-13 2022-06-16 タケダ ワクチン，インコーポレイテッド 小児及び若年成人のデングウイルスに対するワクチンの組成物及び方法

Also Published As

Publication number Publication date
WO2013188315A1 (en) 2013-12-19
JP2018090618A (ja) 2018-06-14
CA2915027A1 (en) 2013-12-19
EP2858668A1 (en) 2015-04-15
TW201402143A (zh) 2014-01-16
NZ630831A (en) 2019-02-22

Similar Documents

Publication Publication Date Title
US9713638B2 (en) Compositions and methods for rapid immunization against dengue virus
JP2018090618A (ja) デングウイルスに対する免疫原性組成物およびワクチンキット
Fahimi et al. Dengue viruses and promising envelope protein domain III-based vaccines
JP5538729B2 (ja) 偽感染性フラビウイルスおよびそれらの使用
US10010600B2 (en) Compositions and methods for administration of vaccines against dengue virus
JP5227172B2 (ja) デングウイルス感染に対するワクチン接種
RU2376374C2 (ru) Вакцина против вируса лихорадки западного нила
US9878031B2 (en) Compositions, methods of administration and uses for trivalent dengue virus formulations
AU2006261943B2 (en) Inactivated chimeric vaccines and related methods of use
EP3426292A1 (en) Live attenuated zika virus vaccine
KR20160027019A (ko) 뎅기 바이러스 백신에 대한 방법 및 조성물
Yan et al. Advancements in dengue vaccines: A historical overview and prospects for following next-generation candidates
CN106999568A (zh) 登革病毒疫苗组合物及其使用方法
Shahana et al. Japanese Encephalitis: An overview of vaccine development

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160610

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20160610

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170404

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20170703

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170830

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20171024